Experimental Biology 2021 Press Materials Available Now

Embargoed press materials are now available for the virtual Experimental Biology (EB) 2021 meeting, featuring cutting-edge multidisciplinary research from across the life sciences. EB 2021, to be held April 27–30, is the annual meeting of five scientific societies bringing together thousands of scientists and 25 guest societies in one interdisciplinary community.

Read more

Announcing Virtual Press Conference for Experimental Biology 2021 Meeting

Reporters are invited to join a live Q&A discussion of exciting research announcements at the forefront of the life sciences during a virtual press conference for the Experimental Biology (EB) 2021 meeting. The press conference will be held online from 1–1:45 p.m. EDT on Monday, April 26, 2021 (RSVP by Friday, April 23).

Read more

Johns Hopkins Medicine Expert Creates Comprehensive Guide to New Diabetes Drugs

New medicines for people who have diabetes seem to pop up all the time. Drugs that help the body break down carbohydrates, drugs that increase excretion of glucose in the urine, drugs that help muscles respond to insulin and drugs that stimulate the pancreas to produce it — the list of pharmaceutical options to treat diabetes gets longer and longer.

Read more

Research News Tip Sheet: Story Ideas from Johns Hopkins Medicine

During the COVID-19 pandemic, Johns Hopkins Medicine Media Relations is focused on disseminating current, accurate and useful information to the public via the media. As part of that effort, we are distributing our “COVID-19 Tip Sheet: Story Ideas from Johns Hopkins” every other Wednesday.

Read more

Genetic testing proves beneficial in prescribing effective blood thinners

A new research paper funded in part by the National Heart, Lung and Blood Institute (NHLBI) shows a clear advantage of genetic testing in helping health care providers choose the appropriate anti-platelet drug. Testing helps determine if a patient carries genetic variants in CYP2C19 that cause loss of its function. These variants interfere with the body’s ability to metabolize and activate clopidogrel, an anti-platelet medication.

Read more

In women, higher body fat may protect against heart disease death, study shows

A new UCLA study shows that while men and women who have high muscle mass are less likely to die from heart disease, it also appears that women who have higher levels of body fat — regardless of their muscle mass — have a greater degree of protection than women with less fat.

Read more

Using Stimuli-Responsive Biomaterials to Understand Heart Development, Disease

The heart cannot regenerate new tissue, because cardiomyocytes, or heart muscle cells, do not divide after birth. However, researchers have now developed a shape memory polymer to grow cardiomyocytes. Raising the material’s temperature turned the polymer’s flat surface into nanowrinkles, which promoted cardiomyocyte alignment. The research is part of the growing field of mechanobiology, which investigates how physical forces between cells and changes in their mechanical properties contribute to development, cell differentiation, physiology, and disease.

Read more

A New Beat Offers Free Online Seminar Examining Disparities in Cardiovascular Care During Heart Month

The Association of Black Cardiologists, Inc. (ABC) and the Cardiovascular Research Foundation (CRF) is offering a complimentary online seminar, “Tackling Disparities in CV Care: A Closer Look at Hypertension and Heart Failure” on Friday February 26, 2021. The program is part of a joint initiative called A New Beat which advocates for women and minorities rising as leaders in cardiology. It aims to foster careers of female and minority cardiologists, who can be poised to improve access to quality care for underserved populations.

Read more

World-Renowned Interventional Cardiologist Establishes Structural Heart Disease Research Fund in Honor of Late Wife

William O’Neill, M.D., director of the Center for Structural Heart Disease at Henry Ford Health System, has donated $1 million to establish the Carol S. O’Neill Structural Heart Disease Research Fund at Henry Ford Health System in honor of his late wife, Carol, who passed away in 2019.

Read more

Heart Valve Collaboratory Announces U.S. Food and Drug Administration Participation in Collaborative Community

The Heart Valve Collaboratory (HVC) announced today that the U.S. Food and Drug Administration (FDA)’s Center for Devices and Radiological Health (CDRH) will participate in this “collaborative community”. A medical “collaboratory” is a forum in which multidisciplinary private and public sector members work together on medical device challenges to achieve aligned outcomes, solve shared problems, and leverage collective opportunities, in the interest of improving patient care.

Read more

American Heart Month: FSU experts available to comment on heart disease topics

By: Kelsey Klopfenstein | Published: February 3, 2021 | 1:14 pm | SHARE: Heart disease is the leading cause of death in the United States. Someone has a heart attack every 39 seconds, and cardiovascular disease claims more lives each year than all forms of cancer combined, according to the American Heart Association’s 2021 Heart Disease and Stroke Statistics Update.

Read more

CRF Offers Free Online Seminar to Help People Jump-Start their Heart Health During Heart Month

The Cardiovascular Research Foundation (CRF) will hold a free online seminar, The Big Three: High Blood Pressure, High Cholesterol, and Diabetes, at 12:00 PM ET on February 22, 2021 hosted by Drs. Nisha Jhalani and Sonia Tolani, cardiologists from NewYork-Presbyterian/Columbia University Irving Medical Center. The seminar is part of a series of “Mini Med Schools” conducted by the CRF Women’s Heart Health Initiative (WHHI), which empowers women with everyday tools they can use to defy heart disease.

Read more

Heart Disease and COVID-19: Focusing on Exercise, Mental Health, and Nutrition are Critical for High-Risk Groups

February is American Heart Month and cardiologists from the Mount Sinai Health System are sharing tips on heart disease prevention to lower the risk of heart attack, stroke, and COVID-19.

Read more

Coconut Oil’s Benefits to Alzheimer’s Ignored in N.Y. Times Attack, Says Dr. Leslie Norins of MCI911.com

Although cardiologists often decry coconut oil because of certain fats it contains, they overlook the growing evidence that other fatty constituents, especially medium-chain triglycerides, may alleviate some cases of mild cognitive impairment and Alzheimer’s disease

Read more

Free Access to TCT Connect Extended for One Year

All educational programming from TCT Connect will be available to registrants for free through October 18, 2021. TCT is the annual scientific symposium of the Cardiovascular Research Foundation (CRF) and the world’s premier educational meeting specializing in interventional cardiovascular medicine.

Read more

Statins can save lives, are they being used?

People who have coronary artery disease, stroke or peripheral artery disease often are prescribed a statin, a cholesterol-lowering drug that reduces the risk of heart attack or stroke.In a recent publication in JAMA Network Open, Mayo Clinic researchers identify trends in statin use across the U.S. among people with these diseases, as well as among those who already had a stroke or transient ischemic attack (TIA). Their data indicate that only about 60% of patients are getting the recommended therapy.

Read more

CTO 2021 Is Now an Online Event: CTO Connect

The Cardiovascular Research Foundation (CRF) has announced that the 2021 Chronic Total Occlusion (CTO) Summit will now take place as a virtual event called CTO Connect. It will take place online February 20-21, 2021.

The conference will feature live case transmissions performed by some of the world’s leading operators along with real-time analysis from world-class faculty members. Live and on-demand sessions will also highlight engaging case-based discussions, challenging cases, and the latest technical developments and refinements in CTO PCI.

Read more

New Non-Invasive Cardiac Test Can Help Physicians Diagnose Heart Disease

MedStar Washington Hospital Center became first in Washington, D.C. and central Maryland to adopt the HeartFlow® Analysis, a first-of-its-kind non-invasive technology to help physicians diagnosis heart disease and determine the next steps in treatment for each patient.

Read more

Mount Sinai’s Valentin Fuster, MD, PhD, Honored by Thai Royal Family for Outstanding Medical Contributions

Thailand’s Royal Family has named Valentin Fuster, MD, PhD, Director of Mount Sinai Heart and Physician-in-Chief of The Mount Sinai Hospital, a winner of the 29th annual Prince Mahidol Award in the field of Medicine.

Read more

All Weight Loss Isn’t Equal For Reducing Heart Failure Risk

DALLAS – Nov. 9, 2020 – Reducing the level of body fat and waist size are linked to a lower risk of heart failure in patients with type 2 diabetes, a study led by UT Southwestern researchers indicates. The findings, reported today in Circulation, suggest that all weight loss isn’t equal when it comes to mitigating the risk of heart disease.

Read more

Randomized Trial Reports Outcomes with Novel, Low Profile Fixed-Wire Drug-Eluting Stent that Facilitates Transradial Access

The OPTIMIZE randomized trial comparing a novel, low-profile drug-eluting stent (DES) facilitating transradial access (TR) and direct stenting (DS) to existing DES did not establish non-inferiority of the new stent based on the prespecified study statistical analysis plan, likely due to the definition of periprocedural target vessel myocardial infarction (TVMI) coupled with a large proportion of high-sensitive cardiac troponin assays used in the trial.

Read more

Randomized Trial Comparing a Nano-Coated Coronary Stent and Shorter DAPT Did Not Meet Non-Inferiority Criteria for Thrombotic Events

For patients undergoing percutaneous coronary intervention (PCI) that also require oral anticoagulation, treatment with a nanotechnology polymer-coated stent plus 14-day dual anti-platelet therapy (DAPT) did not reduce bleeding or establish non-inferior outcomes for thrombotic events compared with a drug-eluting stent (DES) and standard three or six-month DAPT therapy.

Read more

Deferral of PCI in FFR-Abnormal Lesions with Preserved Coronary Flow Reserve Is Not Associated with Similar Outcomes as Untreated Lesions with Normal FFR

A new observational study of deferred lesions following combined fractional flow reserve (FFR) and coronary flow reserve (CFR) assessments found that untreated vessels with abnormal FFR but intact CFR do not have non-inferior outcomes compared to those with an FFR greater than 0.8 and a CFR greater than or equal to two when treated medically.

Read more

Physiology-guided Percutaneous Coronary Intervention Optimization Strategy May Lead to Improved Outcomes

Results from the randomized controlled TARGET FFR trial show that while a physiology-guided percutaneous coronary intervention (PCI) optimization strategy did not achieve a significant increase in the proportion of patients with final FFR ≥0.90, it reduced the proportion of patients with a residual FFR ≤0.80 following PCI.

Read more

Fractional Flow Reserve Derived from Computed Tomography Coronary Angiography Did Not Significantly Reduce Costs But Reduced Rates of Invasive Coronary Angiography

In the FORECAST randomized clinical trial, the use of fractional flow reserve management derived from computed tomography (FFRCT) did not significantly reduce costs but did reduce the use of invasive coronary angiography (ICA).

Read more

Trial Finds that Interventional Closure of Residual Atrial Septal Defect One-Month Post Transcatheter Mitral Valve Repair Was Not Superior to Medical Treatment

The MITHRAS randomized clinical trial found that interventional closure of an iatrogenic atrial septal defect (iASD) driven by transcatheter mitral valve repair (TMVR) was not superior to conservative medical treatment with regard to the primary endpoint of change in six-minute walking distance.

Read more

Randomized Trial Studies Device Designed to Reduce Embolic Events in Patients Undergoing TAVR

The REFLECT II randomized clinical trial evaluating the safety and efficacy of a device designed to reduce cerebral embolization and ischemic stroke, complications of transcatheter aortic valve replacement (TAVR), found that the device met the primary safety endpoint compared to historical controls but did not demonstrate superiority of the device for the primary hierarchical efficacy endpoint.

Read more

Meta-Analysis of Bivalirudin vs. Heparin in Patients with MI Examines Mortality and Bleeding Rates

An individual patient data pooled analysis comparing the use of bivalirudin versus heparin in heart attack patients undergoing percutaneous coronary intervention (PCI) found that bivalirudin use was associated with similar overall rates of 30-day mortality across all heart attack patients, but lower rates of serious bleeding events. Moreover, mortality was reduced in patients with ST-segment elevation myocardial infarction (STEMI) who were treated with a post-PCI bivalirudin infusion.

Read more

Combined FFR and OCT Imaging Can Improve Accuracy of High-Risk Lesion Identification in Patients with Diabetes

Data from COMBINE (OCT-FFR) found that the use of FFR combined with OCT imaging can help improve the accuracy of high-risk lesion identification in patients with diabetes. Findings were reported today at TCT Connect, the 32nd annual scientific symposium of the Cardiovascular Research Foundation (CRF). TCT is the world’s premier educational meeting specializing in interventional cardiovascular medicine.

Read more

NIRS-IVUS Imaging Can Help Identify High-Risk Plaques That Can Lead to Adverse Outcomes

ew data from the PROSPECT II study shows that NIRS-IVUS intracoronary imaging can help identify angiographically non-obstructive lesions with high-risk characteristics for future adverse cardiac outcomes. Findings were reported today at TCT Connect, the 32nd annual scientific symposium of the Cardiovascular Research Foundation (CRF). TCT is the world’s premier educational meeting specializing in interventional cardiovascular medicine.

Read more